Mandaviya meets WHO chief scientist, discusses health body nod for Covaxin

Mandaviya on Thursday met WHO Chief Scientist Dr Soumya Swaminathan and held discussions over the global health body's approval for Bharat Biotech's COVID-19 vaccine Covaxin

Mansukh lal Mandaviya, WHO Chief Scientist Soumya Swaminathan
Union Health Minister Mansukh lal Mandaviya with WHO Chief Scientist Soumya Swaminathan
Press Trust of India New Delhi
2 min read Last Updated : Aug 12 2021 | 7:08 PM IST

Union Health Minister Mansukh Mandaviya on Thursday met WHO Chief Scientist Dr Soumya Swaminathan and held discussions over the global health body's approval for Bharat Biotech's COVID-19 vaccine Covaxin.

Held a meeting with Dr Soumya Swaminathan, Chief Scientist of @WHO. We had a productive discussion on WHO's approval of @BharatBiotech's COVAXIN. @DoctorSoumya also appreciated India's efforts for the containment of #COVID19, Mandaviya tweeted.

All documents required for Emergency Use Listing (EUL) have been submitted by Bharat Biotech for COVID-19 vaccine Covaxin to the World Health Organization (WHO) as of July 9 and the review process by the global health body has commenced, the Rajya Sabha was told last month.

Responding to question on whether it has come to the notice of the government that Covaxin used in India as Covid vaccine is not recognised by many countries, Minister of State for Health Bharati Pravin Pawar in a written reply said, The Government of India is aware that Covaxin at present is not part of WHO Emergency Use Listing (EUL).

Elaborating on efforts that have been made by the government to resolve this issue, Pawar said, "All documents required for Emergency Use Listing (EUL) have been submitted by Bharat Biotech International Ltd. to WHO as of 9th July 2021. The review process by WHO has commenced. WHO usually takes up to six weeks to decide on Emergency Use Listing (EUL) submissions."

Developed by Bharat Biotech in partnership with National Institute of Virology and the Indian Council of Medical Research, Covaxin was approved for emergency use on January 3. Trial results later showed the vaccine has an efficacy of 78 per cent.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusMansukh Lal MandaviyaWorld Health OrganizationBharat BiotechCoronavirus VaccineVaccination

First Published: Aug 12 2021 | 7:08 PM IST

Next Story